Robust Growth in the Geographic Atrophy Market Driven by Aging Population and Technological AdvancesPune, Sept. 20, 2024 ...

Delays in treatment for the rare genetic condition could lead to progressive muscle weakness and irreversible loss in motor ...

The following is a summary of “Frequency and Longitudinal Course of Behavioral and Neuropsychiatric Symptoms in Participants ...

A recent analysis investigated the state of metabolic disruption experienced by patients with spinal muscular atrophy (SMA), ...

This CHMP opinion was made despite broad support for pegcetacoplan from the European retina community and multiple dissenting votes by CHMP members who supported a path to approval.” “We have seen the ...

Researchers from Ajou University presented data from a preclinical study that aimed to assess the potential of using the histone deacetylase (HDAC) inhibitor LMK-235 for the prevention of diabetic ...

Apellis Pharmaceuticals, Inc. (APLS) announced on Friday that the Committee for Medicinal Products for Human Use or CHMP of the ...

Children with spinal muscular atrophy (SMA) experience benefits from receiving a disease-modifying gene therapy, but many ...

Findings suggest Mediterranean and green-MED diets improve brain health, with polyphenols contributing to younger brain age ...

Phase 3 SAGA trial has revealed that Gildeuretinol clinically, meaningfully and safely reduced geographic atrophy lesions ...

The decision against Syfovre’s approval follows efforts by Apellis to have reviewers reevaluate clinical evidence multiple times and, according to an analyst, will lead to a restructuring of the ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shares are moving lower Friday after the Committee for Medicinal Products for ...